Monday, October 13, 2014 9:29:48 AM
Analysts at Barclays initiated coverage on shares of Foamix Pharmaceuticals (NASDAQ: FOMX) with a Overweight rating.
The target price for Foamix Pharmaceuticals is set to $11.
Foamix Pharmaceuticals' shares fell 3.61% to close at $5.08 on Friday
Pharmaceuticals (NASDAQ:FOMX) | Benzinga
http://www.benzinga.com/analyst-ratings/initiation/14/10/4916444/barclays-initiates-foamix-pharmaceuticals-at-overweight
It may not be much money, but it's mine dammit to hell, not 'yours'.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM